Skip to main content
Equibles
BBIO logo

BBIO · BridgeBio Pharma, Inc. · Investor Relations

Track BBIO — free

Use BBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$65.80 -0.17 (-0.26%) At close · Sep 30
Russell 1000 member Rebalance outlook locked
Market Cap
$12.90B
Shares
195.49M
Volume · Sep 30 2.82M Avg daily vol (3M) 2.75M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-23 Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
2026-09-18 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-09 Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
2026-09-02 BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
2026-09-01 BridgeBio to Participate in September Investor Conferences
2026-08-31 BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
2026-08-30 Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
2026-08-26 BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
2026-08-24 BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
2026-08-14 BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
2026-08-13 BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
2026-08-11 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
2026-08-03 BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
2026-07-22 BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
2026-07-10 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
2026-07-01 BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
2026-06-28 BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
2026-06-23 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-06-22 BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
2026-05-27 BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
2026-05-12 BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
2026-05-11 Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
2026-05-08 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Past events

Date Event Type
2026-09-23 Bernstein Insights Healthcare Leaders and Disruptors 2026 Event
2026-09-15 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-10 2026 Cantor Global Healthcare Conference Conference
2026-09-09 21st Annual Wells Fargo Healthcare Conference Conference
2026-08-10 BridgeBio Q2 Earnings Call Earnings call
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-04 2026 Jefferies Global Healthcare Conference Conference
2026-05-12 BoA Securities Health Care Conference 2026 Conference
2026-05-07 BridgeBio Q1 Earnings Call Earnings call
2026-03-11 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-10 Leerink Partners Global Healthcare Conference Conference
2026-03-02 TD Cowen 46th Annual Healthcare Conference Conference
2026-02-24 BridgeBio Q4 Earnings Call Earnings call
2026-02-12 Achondroplasia PROPEL Phase 3 Topline Results Webinar Event
2026-01-12 44th Annual J.P. Morgan Healthcare Conference Conference
2026-01-09 Achondroplasia Investor Webinar Event
2025-12-03 8th Annual Evercore Healthcare Conference Conference
2025-12-02 37th Annual Piper Sandler Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference Conference
2025-11-10 UBS Global Healthcare Conference Conference
2025-10-29 BridgeBio Q3 Earnings Call Earnings call
2025-10-29 Autosomal Dominant Hypocalcemia Type 1 (ADH1) CALIBRATE Phase 3 Topline Results Webinar Event
2025-10-27 Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar Event
2025-09-10 Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Event
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference

Source: https://investor.bridgebio.com/

Key facts CIK 1743881 CUSIP 10806X102 13F (30d) 13 filings 12 filers Visit website Investor relations